Adverse Effects of Synthetic Cannabinoids: Management of Acute Toxicity and Withdrawal
Current Psychiatry Reports April 14, 2016 DOI: 10.1007/s11920-016-0694-1 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Review Peer reviewed |
|---|---|
| Population | Synthetic cannabinoid users and cannabis smokers in the New York City metropolitan area (2012–2015) |
| Duration | 3.5-year survey period (2012–2015) |
| Key findings | The authors argue that risks of synthetic cannabinoids include not only unpredictable, severe acute intoxication but also dependence and withdrawal from daily use, a problem they say is often overlooked. Survey data from the New York City area (2012–2015) indicate a subset of cannabis smokers use these drugs daily. Withdrawal is not systematically characterized, though benzodiazepines and quetiapine have been reported to relieve some symptoms; the authors call for empirical studies of acute effects, withdrawal, and treatment. |
Abstract
Although several chemical structural classes of synthetic cannabinoids (SCs) were recently classified as Schedule I substances, rates of use and cases of serious toxic effects remain high. While case reports and media bring attention to severe SC toxicity, daily SC use resulting in dependence and withdrawal is a significant concern that is often overlooked when discussing the risks of these drugs. There is a rich literature on evidence-based approaches to treating substance use disorders associated with most abused drugs, yet little has been published regarding how to best treat symptoms related to SC dependence given its recency as an emerging clinically significant issue. This review provides a background of the pharmacology of SCs, recent findings of adverse effects associated with both acute intoxication and withdrawal as a consequence of daily use, and treatment approaches that have been implemented to address these issues, with an emphasis on pharmacotherapies for managing detoxification. In order to determine prevalence of use in cannabis smokers, a population at high risk for SC use, we obtained data on demographics of SC users, frequency of use, and adverse effects over a 3.5-year period (2012–2015) in the New York City metropolitan area, a region with a recent history of high SC use. While controlled studies on the physiological and behavioral effects of SCs are lacking, it is clear that risks associated with using these drugs pertain not only to the unpredictable and severe nature of acute intoxication but also to the effects of long-term, chronic use. Recent reports in the literature parallel findings from our survey, indicating that there is a subset of people who use SCs daily. Although withdrawal has not been systematically characterized and effective treatments have yet to be elucidated, some symptom relief has been reported with benzodiazepines and the atypical antipsychotic, quetiapine. Given the continued use and abuse of SCs, empirical studies characterizing (1) SCs acute effects, (2) withdrawal upon cessation of use, and (3) effective treatment strategies for SC use disorder are urgently needed.
Citations in the library
Cited by 19
- Trends in MDMA‐related mortality across four countries Addiction March 19, 2021
- Clinical withdrawal symptom profile of synthetic cannabinoid receptor agonists and comparison of effects with high potency cannabis. Psychopharmacology May 1, 2022
- Adverse clinical effects associated with the use of synthetic cannabinoids: A systematic review. Drug and Alcohol Dependence July 1, 2025
- Potential neonatal toxicity of new psychoactive substances. Pharmacology & Therapeutics August 1, 2023
- New psychoactive substances and the risks of consumption in children and adolescents Romanian Journal of Pediatrics December 31, 2019
and 14 more in the library
Cites 13
- Beyond THC: The New Generation of Cannabinoid Designer Drugs Frontiers in Behavioral Neuroscience 2011
- Baths Salts, Spice, and Related Designer Drugs: The Science Behind the Headlines Journal of Neuroscience November 12, 2014
- Repeated administration of phytocannabinoid Δ(9)-THC or synthetic cannabinoids JWH-018 and JWH-073 induces tolerance to hypothermia but not locomotor suppression in mice, and reduces CB1 receptor expression and function in a brain region-specific manner. Pharmacological Research December 2015
- Synthetic cannabinoids: epidemiology, pharmacodynamics, and clinical implications. Drug and Alcohol Dependence November 1, 2014
- The cannabinoid agonist HU-210: pseudo-irreversible discriminative stimulus effects in rhesus monkeys. European Journal of Pharmacology March 15, 2014
and 8 more in the library